Hashan is not here at SNT to make a few pips,,that's for sure..
The interim data from SNT 5505 is just as critical to SNT 6302.. below is why
Given that SNT-5505 is the most advanced asset and the pressing need for new treatment options in MF, our primary focus in this piece will remain on this critical indication.
Both the drugs for skin scarring (SNT-6302) and for MF, however, share the same biological target – an enzyme called lysyl oxidase (LOX). LOX is a key enzyme in fibrosis or scar tissue formation and is involved in crosslinking of collagen. Fibrosis is a part of the natural healing process however excessive scar tissue builds up in various diseases, including cancer and rare autoimmune conditions. In both MF and skin scarring, inhibiting LOX could have a meaningful impact, and insights from one indication could affect the probability of success in the other.
TUESDAY is ON IT"S WAY ....... anyone have a handle on the exact time of the Presentation? NZT
